Marina Frimer, MD, Discusses Maintenance Niraparib in Platinum-Sensitive Uterine Serous Cancer


Marina Frimer, MD, spoke about the goals of a phase 2 trial and how it can impact patients with platinum-sensitive recurrent uterine serous carcinoma.

At The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, CancerNetwork® spoke with Marina Frimer, MD, associate chief of Research & Academic Development Central Region and associate professor at the Donald and Barbara Zucker School of Medicine at Hofsta/Nortwell Health in New Hyde Park, New York, about the rationale behind an ongoing phase 2 trial (NCT04080284) of niraparib (Zejula) for patients with stage III or IV platinum-sensitive recurrent uterine cancer. Frimer also spoke about how these results can impact future research in the field.


PARP inhibitors have shown significant evidence in treatment of serous ovarian cancer, and uterine serous cancer [which] often presents in advanced stage. There are also studies that have shown that uterine serous cancer can exhibit the BRCAness of genomic alterations that we see with ovarian cancer. That’s why we felt that PARP inhibitors should be tried in this type of tumor.

The goals for the trial were to evaluate progression-free survival [PFS], overall survival, and overall response rate [ORR] at 1 year, with secondary outcomes focusing on [results at] 2 and 3 years. The design for this trial includes a 2-stage Simon design, where we’re looking for a difference that’s greater than 40% compared with no difference of the null hypothesis, which is less than 20% change in PFS and ORR.

At this time, we have limited ability to treat patients who recur with uterine serous carcinoma. In the future, if there is promise with maintenance PARP therapy, then we hope that we will have a maintenance option for these patients as well as an option at the time of recurrence.


Frimer M, Nizam A, Sison C, et al. Phase II trial of maintenance niraparib in patients with stage III, stage IV or platinum-sensitive recurrent uterine serous carcinoma. Presented at: 2022 SGO Annual Meeting on Women’s Cancer; March 18-21, 2022. Phoenix, Arizona.

Related Videos
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Ongoing genomic profiling analyses in the ASC4FIRST trial may further determine which patients with CML may benefit from treatment with asciminib.
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
Related Content